Learning outcomes
By the end of this lesson you should be able to: locate each diuretic class at its site in the nephron and state the transporter it inhibits; compare loop, thiazide and potassium-sparing diuretics by efficacy of sodium excretion, onset and duration; predict the electrolyte and metabolic consequences of each class; describe the roles of osmotic and carbonic anhydrase inhibitors; and construct a rational combination regimen for resistant oedema while spotting the traps (hypokalaemia, hyponatraemia, gout, oedema, potentiated toxicity).
Prerequisites
Lessons 1 to 6, and the renal module of the physiology course — the nephron segments, the loop of Henle and the countercurrent mechanism.
The big idea
The nephron is a sequence of reabsorptive sites, and the classes map onto them: around 65 per cent of filtered sodium is reabsorbed in the proximal tubule, 25 per cent in the loop of Henle, 5 to 10 per cent in the distal convoluted tubule, and a final 1 to 2 per cent in the collecting duct. A drug cannot exceed its segment's share, so a loop diuretic has the largest ceiling (20 to 25 per cent of filtered sodium) and a potassium-sparing agent the smallest (about 2 per cent). That single fact explains why a loop diuretic is chosen for pulmonary oedema while a thiazide serves hypertension, and why adding a thiazide to a loop — sequential nephron blockade — produces a diuresis greater than either drug alone.
The nephron and its drugs
| Nephron segment | Sodium reabsorbed | Transporter | Drug acting there |
|---|---|---|---|
| Proximal convoluted tubule | About 65 per cent (bicarbonate and glucose with it) | Sodium-hydrogen exchanger, sodium-phosphate cotransporter | Carbonic anhydrase inhibitors (acetazolamide) |
| Thick ascending limb of the loop of Henle | About 25 per cent | Sodium-potassium-2 chloride cotransporter | Loop diuretics (furosemide, bumetanide) |
| Distal convoluted tubule | About 5 to 10 per cent | Sodium-chloride cotransporter | Thiazides and thiazide-like diuretics (indapamide) |
| Collecting duct (principal cells) | The final 1 to 2 per cent | Epithelial sodium channel (ENaC) driven by aldosterone | Amiloride, triamterene; spironolactone and eplerenone block the aldosterone receptor above it |
| Descending limb and collecting duct | Water follows solute | Aquaporins under antidiuretic hormone influence | Osmotic agents (mannitol); antagonists treat nephrogenic diabetes insipidus by a different route |
The three workhorse classes
| Class | Example drugs | Site and mechanism | Main indications |
|---|---|---|---|
| Loop diuretics | Furosemide, bumetanide, torasemide | Inhibit the sodium-potassium-2 chloride cotransporter of the thick ascending limb; collapse of the medullary gradient abolishes the kidney's concentrating ability, giving a profuse diuresis | Acute pulmonary oedema, chronic heart failure, cirrhosis with ascites, chronic kidney disease, hypercalcaemia (with saline) |
| Thiazide and thiazide-like diuretics | Indapamide, chlortalidone, bendroflumethiazide | Inhibit the sodium-chloride cotransporter of the distal convoluted tubule; a modest diuresis with long-term fall in peripheral resistance | Hypertension, mild heart failure with a loop agent, kidney stones from hypercalciuria, nephrogenic diabetes insipidus |
| Potassium-sparing diuretics | Spironolactone, eplerenone, amiloride, triamterene | Block the epithelial sodium channel directly or the aldosterone mineralocorticoid receptor that drives it, so potassium is retained while a little sodium is lost | Heart failure (mortality benefit), resistant hypertension, cirrhosis with ascites, primary hyperaldosteronism |
Furosemide is the loop diuretic in most formularies: intravenous it acts within five minutes, oral within an hour, and it is the drug of choice for the acute drowning sensation of pulmonary oedema. Bumetanide is better absorbed orally and is preferred when gut oedema blunts furosemide uptake in decompensated failure. Spironolactone is the only diuretic with survival benefit in heart failure, which is why it sits alongside the RAS blocker and beta-blocker rather than being a mere symptom drug.
Electrolyte and metabolic consequences
| Class | Potassium | Sodium | Other predictable effects |
|---|---|---|---|
| Loop diuretics | Low (hypokalaemia) — more sodium delivered to the collecting duct wastes potassium | Low, with volume depletion | Hypomagnesaemia, metabolic alkalosis, hypocalcaemia, hyperuricaemia, ototoxicity (dose-related and additive with aminoglycosides) |
| Thiazide and thiazide-like diuretics | Low (hypokalaemia) | Low — the classic cause of diuretic-induced hyponatraemia, especially in older women | Hyperuricaemia precipitating gout, hyperglycaemia, hypercholesterolaemia, hypercalcaemia, erectile dysfunction |
| Potassium-sparing diuretics | High (hyperkalaemia), dangerous with an ACE inhibitor or ARB | No direct fall | Spironolactone gives gynaecomastia and menstrual irregularity through progesterone activity; eplerenone is the progesterone-clean alternative |
| Osmotic diuretics | Initial rise then fall | Transient rise then fall | Expansion of plasma volume before the diuresis, risking pulmonary oedema in heart failure |
| Carbonic anhydrase inhibitors | Low | Variable | Metabolic acidosis (bicarbonate wasting), paraesthesiae, sedation, and renal stone risk from hypocitraturia |
NoteTwo interactions are the exam favourites. Non-steroidal anti-inflammatory drugs oppose every diuretic by inhibiting renal prostaglandins that maintain the afferent perfusion, so a patient on indapamide plus ibuprofen for back pain loses the diuresis and gains renal risk. And a loop diuretic with an aminoglycoside adds cochlear and renal toxicity, because both are accumulated in the tubular fluid and the hair cells.
Osmotic and carbonic anhydrase inhibitors
Mannitol is an osmotic diuretic: filtered but not reabsorbed, it holds water in the tubule and draws fluid out of the tissues. Its modern uses are few — to lower intracranial pressure and intraocular volume before ophthalmological surgery, and to flush myoglobin in early rhabdomyolysis — and its expansion of plasma volume before the diuresis makes it unsafe in established heart failure. Acetazolamide inhibits carbonic anhydrase, causing bicarbonate wasting and a metabolic acidosis that is exploited in three niches: glaucoma (reducing aqueous humour formation), altitude sickness (the acidosis drives ventilation before acclimatisation), and alkalinisation of the urine, for example alongside cystinuria stones or salicylate poisoning.
Clinical practice: why diuresis fails
When oedema becomes resistant, the causes are pharmacodynamic and adherence-related before they are exotic: salt and fluid intake exceed the prescribed ceiling, renal perfusion is poor so the drug never reaches its segment, non-steroidal drugs are being taken, or the downstream nephron has hypertrophied and reabsorbs the sodium the loop leaves behind. The answers follow the pharmacology — restrict salt, add an agent that acts downstream (a thiazide to the loop), check the adherence, review the interacting drugs, and only then escalate doses. Daily weights are the most reliable bedside measure of the response, and a rising creatinine during diuresis demands the fluid balance be reconsidered before the next dose.
Common mistakes
Watch outPrescribing a loop diuretic for ankle oedema from amlodipine. That oedema is capillary leakage from arteriolar dilation, not sodium retention; the diuretic depletes potassium and volume while doing nothing for the swelling.
Watch outStacking an ACE inhibitor, spironolactone and trimethoprim and being surprised by hyperkalaemia. Each blocks potassium loss — the RAS blockade, the mineralocorticoid receptor, and the epithelial sodium channel that trimethoprim inhibits as an amiloride-like side effect — and an elderly patient with renal impairment can arrive at seven without any single drug being misused.
Watch outRunning the thiazide dose up to chase oedema. Thiazides plateau: beyond the equivalent of a small dose of bendroflumethiazide the blood-pressure effect stops growing while hyponatraemia and gout risk climb.
Watch outForgetting that a potassium-sparing diuretic merely balances loss elsewhere. Amiloride's hyperkalaemia is a predictable intention in the fixed combination with furosemide, not an allergic accident — but in a patient on a RAS blocker and with chronic kidney disease it is the one addition that must be potassium-checked first.
Check your understanding
Why does adding a thiazide to a loop diuretic produce a diuresis greater than either drug alone?
Why is furosemide the drug of choice for acute pulmonary oedema rather than a thiazide?
A patient on furosemide for heart failure suddenly loses the diuresis and her weight rises. Which common drugs blunt the effect?
Multiple choice
Which transporter is inhibited by furosemide?
Which metabolic disturbance is characteristic of thiazide diuretics rather than loop diuretics?
A patient with heart failure takes furosemide, ramipril and spironolactone. Which electrolyte must be monitored most carefully?
Which diuretic has a demonstrated mortality benefit in heart failure?
Which adverse effect is characteristic of spironolactone but not eplerenone?